

INVITATION

22nd - 23rd
SEPT
2022

5th Workshop on Solid Organ Transplantation (SOT) and Extracorporeal Photopheresis (ECP): Clinical Evidence and Sharing Best Practice

Novotel Monte Carlo, Monaco

This information is intended for healthcare professionals in Europe

Chairs Prof. Markus Barten, University Heart & Vascular Center Hamburg, Germany
Prof. Andrew Fisher, Newcastle University, United Kingdom
Prof. Alexandre Hertig, Foch Hospital, Suresnes, France

PROGRAMME

DAY 1 – 22 SEPTEMBER 2022

- 12:00 – 13:00 **Lunch**
- 13:00 – 13:15 **Welcome from Therakos/Mallinckrodt**
Dennis Junker
- 13:15 – 13:30 **Welcome and introductions**
All Chairs
- 13:30 – 14:00 **Proposed immunological mechanism of ECP in SOT**
Dr James Hutchinson, University Hospital Regensburg, Germany
- 14:00 – 14:10 **Breakout session instructions**
- 14:10 – 14:30 **Breakout sessions**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig
- 14:30 – 14:50 **Coffee break**

SESSION 1: INDUCTION AND/OR PREVENTION THERAPY

- 14:50 – 15:10 **ECP as immunosuppressive sparing option in high-risk patients after Heart Transplant (HTX)**
Dr Johannes Gökler, Medical University Vienna, Austria
- 15:10 – 15:30 **ECP as a preventative therapeutic option in highly sensitised de novo KTX recipients**
Prof. Fritz Diekmann, Hospital Clínic, Barcelona, Spain
- 15:30 – 15:50 **Prophylactic Use of ECP after lung transplantation**
Prof. Peter Jaksch, Medical University Vienna, Austria
- 15:50 – 16:10 **Breakout sessions**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig
- 16:10 – 16:30 **Coffee break**

SESSION 2: ACUTE AND RECURRENT CELLULAR REJECTIONS

- 16:30 – 16:50 **Real-World use of ECP after HTX – Results of a Pan-European multicentric study**
Dr Balazs Sax, Semmelweis University Heart and Vascular Center, Hungary
- 16:50 – 17:10 **Real-world use of ECP in KTX patients**
Prof. Jean-Francois Augusto, Angers University Hospital, France
- 17:10 – 17:30 **Breakout sessions**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig
- 17:30 – 18:10 **Breakout session highlights**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig
- 18:10 – 18:15 **Wrap up and close day 1**
- 20:00 **Dinner**

DAY 2 – 23 SEPTEMBER 2022

SESSION 3: INFECTIONS, MALIGNANCIES, IMMUNOSUPPRESSION SPARING

- 08:50 – 09:10 **Usage of ECP after LuTX and development of infections**
Dr Martin Carby, Harefield Hospital, United Kingdom
- 09:10 – 09:30 **BK virus (BKV) nephropathy, Post-transplant Lymphoproliferative Disorder (PTLD), a possible role for ECP?**
Prof. Jean-Francois Augusto, Angers University Hospital, France
- 09:30 – 09:50 **Breakout sessions**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig
- 09:50 – 10:10 **Coffee Break**

SESSION 4: ABMR

- 10:10 – 10:30 **Subclinical rejection and treatment of Antibody-mediated Rejection (ABMR) in HTX recipients**
Dr Eric Epailly, Strasbourg University Hospital, France
- 10:30 – 10:50 **Molecular impact of ECP treatment in patients with chronic ABMR after KTX**
Dr Arnaud Lionet, Huriez Hospital, Lille, France
- 10:50 – 11:10 **Vienna experience on ECP use in the treatment pathway of ABMR after LuTX**
Prof. Peter Jaksch, Medical University Vienna, Austria
- 11:10 – 11:30 **Breakout sessions**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig

SESSION 5: DATA, ETHICS, ADHERENCE

- 11:30 – 11:50 **Natural Killer (NK) mediated rejection**
Dr Alice Koenig, Claude Bernard University Lyon 1, France
- 11:50 – 12:10 **National Institute for Health and Care Research (NIHR) trial, data needs Randomised Control Trial (RCT) vs Real-world Evidence (RWE)**
Prof. Andrew Fisher, Newcastle University, United Kingdom
- 12:10 – 12:30 **Adherence**
Dr Celine Goeminne, Institut Coeur Poumon, Lille, France
- 12:30 – 13:00 **Breakout session highlights**
Prof. Barten, Dr Epailly, Prof. Fisher, Dr Gökler and Prof. Hertig
- 13:00 – 13:05 **Wrap up and meeting closure**
- 13:05 – 14:05 **Lunch**

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.

Follow the
Therakos Institute



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2022 Mallinckrodt. Item code: EU-2200101. Date of preparation: July 2022.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.